Cherry-Picking Historical Data to Legitimize Contemporary Practice: Should Diabetic Status Influence Decision-Making in Complex CAD?

[1]  R. Frye,et al.  SYNTAX Score and Long-Term Outcomes: The BARI-2D Trial. , 2017, Journal of the American College of Cardiology.

[2]  P. Serruys,et al.  Balancing idealism with realism to safeguard the welfare of patients: The importance of Heart Team led decision-making in patients with complex coronary artery disease , 2016, Indian heart journal.

[3]  A. Yeung,et al.  Trial of everolimus-eluting stents or bypass surgery for coronary disease. , 2015, The New England journal of medicine.

[4]  P. Serruys,et al.  The triad of residual ischaemia, plaque burden, and plaque vulnerability: a known known?…a known unknown?...or an unknown unknown? , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[5]  P. Kolh,et al.  [2014 ESC/EACTS Guidelines on myocardial revascularization]. , 2014, Kardiologia polska.

[6]  J. Rutledge,et al.  Coronary artery revascularization in patients with diabetes mellitus. , 2013, Circulation.

[7]  P. Serruys,et al.  Widening clinical applications of the SYNTAX Score , 2013, Heart.

[8]  P. Serruys,et al.  The SYNTAX score and its clinical implications , 2013, Heart.

[9]  Antonio Colombo,et al.  Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial , 2013, The Lancet.

[10]  Antonio Colombo,et al.  Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II , 2013, The Lancet.

[11]  Akshay S. Desai,et al.  Strategies for multivessel revascularization in patients with diabetes. , 2012, The New England journal of medicine.

[12]  Sankey V. Williams,et al.  2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Ass , 2012, Journal of the American College of Cardiology.

[13]  E. Steyerberg,et al.  Incidence and multivariable correlates of long-term mortality in patients treated with surgical or percutaneous revascularization in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial. , 2012, European heart journal.

[14]  E. Steyerberg,et al.  A global risk approach to identify patients with left main or 3-vessel disease who could safely and efficaciously be treated with percutaneous coronary intervention: the SYNTAX Trial at 3 years. , 2012, JACC: Cardiovascular Interventions.

[15]  Helmut Baumgartner,et al.  ESC / EACTS Guidelines on myocardial revascularization , 2014 .

[16]  P. Serruys,et al.  Contemporary and evolving risk scoring algorithms for percutaneous coronary intervention , 2011, Heart.

[17]  S. Scolletta,et al.  The easier, the better: age, creatinine, ejection fraction score for operative mortality risk stratification in a series of 29,659 patients undergoing elective cardiac surgery. , 2011, The Journal of thoracic and cardiovascular surgery.

[18]  R. Steinzor.  Testimony of Rena Steinzor…before the U.S. House of Representatives, Energy and Commerce Committee, Subcommittee on Environment and Economics. 112th Congress, 1st Session (2011). , 2011 .

[19]  Antonio Colombo,et al.  5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. , 2010, Journal of the American College of Cardiology.

[20]  G. Pelissero,et al.  Risk of Assessing Mortality Risk in Elective Cardiac Operations: Age, Creatinine, Ejection Fraction, and the Law of Parsimony , 2009, Circulation.

[21]  Maria Mori Brooks,et al.  A randomized trial of therapies for type 2 diabetes and coronary artery disease. , 2009, The New England journal of medicine.

[22]  A. Bogers,et al.  The clinical outcome after coronary bypass surgery: a 30-year follow-up study. , 2008, European heart journal.

[23]  R. Virmani,et al.  Frequency and distribution of thin-cap fibroatheroma and ruptured plaques in human coronary arteries: a pathologic study. , 2007, Journal of the American College of Cardiology.

[24]  D. Taggart.  Thomas B. Ferguson Lecture. Coronary artery bypass grafting is still the best treatment for multivessel and left main disease, but patients need to know. , 2006, The Annals of thoracic surgery.

[25]  J. Beckman,et al.  Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I , 2013, European heart journal.

[26]  M. Posternak,et al.  Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? , 2002, The American journal of psychiatry.

[27]  C. K. Kirby.  THE AMERICAN ASSOCIATION FOR THORACIC SURGERY , 1962 .